AnaptysBio Authorizes $100 Billion Buyback Plan

Biotechnology company plans to repurchase over 5 million shares

Mar. 28, 2026 at 2:05am

Got story updates? Submit your updates here. ›

AnaptysBio (NASDAQ:ANAB), a biotechnology company based in San Diego, California, has announced that its Board of Directors has approved a $100 billion stock repurchase program. The buyback authorization allows the company to repurchase up to 5,352,316.2% of its outstanding shares through open market purchases.

Why it matters

Stock buyback plans are often seen as a sign that a company's management believes its shares are undervalued. This move by AnaptysBio could indicate confidence in the company's future prospects and a desire to return value to shareholders.

The details

The $100 billion buyback program will allow AnaptysBio to repurchase a significant portion of its outstanding shares. The company plans to execute the buybacks through open market purchases. Repurchasing shares can help boost a company's stock price by reducing the number of shares available on the market.

  • AnaptysBio's Board of Directors authorized the $100 billion buyback plan on March 27, 2026.

The players

AnaptysBio

A clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation.

Got photos? Submit your photos here. ›

What’s next

The company will now begin executing the $100 billion buyback program through open market purchases.

The takeaway

AnaptysBio's decision to authorize a substantial $100 billion buyback program suggests the company's management is confident in the long-term prospects of the business and believes its shares are currently undervalued by the market.